Enabling accurate biological analysis through automation

12+

Years solving bioassay bottlenecks

50+

peer-reviewed publications

300+

users worldwide and growing

Enabling accurate biological analysis through automation

Spun out of the Agency for Science, Technology, and Research (A*STAR) in Singapore, Curiox brings together decades of scientific and engineering expertise in surface chemistry and life science instrumentation with the goal of overcoming critical challenges that slow the pace of life science research.

By focusing on common assay steps where miniaturization and automation are currently underutilized, we’ve developed innovative technologies that simultaneously improve both productivity and data quality.

We look forward to ushering in the next generation of innovations that accelerate the pace of life science research, diagnostics, and therapeutics discovery and development.

H-Tee the helpful robot

Our mission is to:

  • Become the gold standard in how cells are processed for analysis
  • Make cell analysis accurate, true to nature, and executable under minimal training
  • Enable therapeutics and diagnostics with readily available, accurate cell analysis

OUR HISTORY

Curiox was founded in 2008 to commercialize DropArray™ technology, which was initially developed by Namyong Kim, PhD and his group at the Institute of Bioengineering and Nanotechnology (IBN), a part of A*STAR. The venture was backed by Nanostart AG and Exploit Technologies, the commercialization arm of A*STAR.

In 2010, we received a large corporate investment from the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange, that greatly accelerated our product development timeline and enabled expansion into global markets.

More recently, we introduced our Laminar Wash™ technology, which automates cell processing and enables highly reproducible and high-throughput cell analysis. This technology has seen strong adoption and sales globally, and we continue to improve and expand this product offering.

In 2019, we completed a Series B round of funding, raising US $15M from a consortium of venture capital organizations including KB Investments, IMM Investments, Quad Investments, HB Investments, DayLI Investments, and SV Investments in Korea.

Cubi the lovable leukocyte

LEADERSHIP TEAM

Namyong-Kim-img
Dr Namyong Kim

Chief Executive Officer (CEO)

Hongtae-bio-1024x768
Mr HongTae Jung

Executive Vice President, CFO

david-bio
David Choiniere

Vice President of Sales and
Marketing North America

BOARD OF DIRECTORS

gioklak
Mr Giok Lak Sim

Board Member

sim
Mr Kok Hwee Sim

Board Member

Namyong-Kim-img
Dr Namyong Kim

Chief Executive Officer (CEO)

aleum-lee-bio-1024x768
Ms Aleum Lee

Board Member

youngtae-hong-bio-2-1024x768
Mr Youngtae Hong

Board Member

Hongtae-bio-1024x768
Mr HongTae Jung

Board Member

JOIN OUR TEAM

Melvin_in_lab-1

Become part of a world leading science and engineering team that invests in the future of its employees and the success of our customers..

Latest News View All

    icon

    October 28, 2021

    Curiox Partners with DKSH to Enable Cell Research in Asia
    icon

    September 29, 2021

    Curiox Joins NIST Flow Cytometry Standards Consortium
    icon

    March 24, 2021

    Curiox Laminar Wash Featured on Charles River Lab’s “Eureka” Science Blog